Navigation Links
Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Date:6/25/2008

proteins encoded by the polynucleotides. Vical's patent coverage includes delivery of linear DNA as well as plasmid DNA.

Currently plasmid DNA vaccines, which are under development against pandemic influenza and other infectious diseases at Vical, are manufactured by bacterial fermentation in standardized equipment with a production time measured in weeks rather than months. While plasmid DNA vaccines offer a significant improvement over conventional vaccine manufacturing technologies, the RapidResponse(TM) DNA vaccine platform could offer further advantages, especially in greater speed of production and lower cost. The company plans to continue development of its plasmid DNA vaccine programs because the technology is much closer to commercial realization in humans.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that coul
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...HESTER, Minn., Nov. 26 ...rd are at significantly increased risk of developi... findings of a Mayo Clinic study published this m...merican Academy of Pediatrics. , , The retr...7 patients with strabismus (misaligned eyes) and c...
(Date:11/26/2008)...dy Expanded to 406 Subjects , , FRANKLIN, M...s Inc. (OTC Bulletin Board: PLCSF) announced today...Food and Drug Administration (FDA) for its U.S. pi...any,s RenalGuard System(TM) and associated therap...y (CIN). , , The FDA also approved PLC,s re...
(Date:11/25/2008)...ISVILLE, Ky., Nov. 25 K...urgeons performed the fifth U.S. hand transplant o... at Louisville,s Jewish Hospital Hand Care Center ...began around noon and was completed shortly after ... http://www.newscom.com/cgi-bin/prnh/20081125/DC4...
(Date:11/25/2008)...TH SAN FRANCISCO, Calif., Nov. 25 ...velopment of novel therapeutics that target,prote...iseases, today,announced that data from two ongoi...iple myeloma will be presented at the upcoming 50t...ology (ASH). Carfilzomib is the first in a new cl...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 1Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 2Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 3Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 23343 1Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 23343 2Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference 23340 1Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference 23340 2Physicians Practice Promotes Key Executives 23337 1Physicians Practice Promotes Key Executives 23337 2
...t Randomized, Placebo-controlled Trial,Ever Conduc...linical Oncology, CHICAGO, June 04, 2007 /PRNewswi...ed, placebo-controlled clinical trial ever,conduct...L) showed,that ONTAK was more than twice as effect... patients with CTCL. [Abstract number 8026],The pr...
...With Follicular Lymphoma Reported,Today at ASCO An...ire/ -- GlaxoSmithKline plc,announced today long-t...e one-week course of frontline treatment with the ...ine I-131 Tositumomab) in,76 patients with newly d...a (NHL). This regimen was found to induce durable ...
Other Medicine Technology:Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
(Date:12/2/2008)...n Service, one of the premier leaders in medical t...ictation transcription, has joined up with TMATT,...zation geared to the betterment of women and child... Lower Westchester County, New York. , ... -- World Wide Dictation Services of New York, ht...
(Date:12/2/2008)...-- The Healthcare group at,Frost & Sullivan (...nnounce that,it will be hosting a free webinar on...rica on Friday 12 December at 16h00 CAT/14h00 GMT....rnh/20081117/FSLOGO ) , Medical insurance a...elatively novel concept in most sub-Saharan Africa...
(Date:12/2/2008)...leading provider of onsite health services and tec... the athletic products company, has selected Marat... health clinics and to provide health services to ... Burlington, VT (PRWEB) Decembe...f onsite employee health services and technology s...
(Date:12/2/2008)...the problem with the holidays is family. Elder ca...regivers of aging parents can bring the joy of the... San Mateo, CA (PRWEB) Decem... holiday season is family, especially aging parent...ch , founder of Encore Management , has a simple ...
Breaking Medicine News(10 mins):Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2Health News:The Future of Financing Health Services in Africa 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3
...n, Deborah Busemeyer, says a man in critical condi...e disease in which the plague bacteria multiply in...County died last week from septicemic form of the ...te from an infected flies or direct contact with i...
...cal College and Hospital has described the critici...ns as baseless. // The superintendent and princip... allegation had no basis. Yesterday around 200 HIV... banner of 'Sanghabaddha' a voluntary organisation...
... reports, ‘Indonesia hasn’t shared the genetic inf...director-general of disease control and environmen...Health, reports that certain things are to be cons...efore any public release and there is more chance ...
...te of British Red Cross (Indonesia), Mark Snelling...ore areas of southern regions of Java island//. O...injured and everyone involved in the relief operat...rs here is an eternity – said latest official repo...
Other Medicine News:
Eyeglass Loupe 3x-5x made with precision optical glass. Ideal for any detail work.
Near PT test card/child recog/ playing cards 5 1/2" X 8".
Near point card/newspaper 8 to 48 point type 5 1/2" X 8".
Near point card 4 1/2 to 24 PT 5 1/2" x 8".
Medicine Products: